I-Monovisc ye-Knee Osteoarthritis

I-Viscosupplement ye-Knee Osteoarthritis

I-Monovisc ingumjovo owodwa we- viscosupplement osetshenziselwa ukuphatha amalunga emadolo abhekene ne- osteoarthritis . Kuyinto injini ye-intra-articular , okusho ukuthi ijojowe ekuhlanganyeleni okuthintekile. I-Monovisc yasungulwa ngu-Anika Therapeutics, Inc. futhi ithola imvume yokumaketha evela e-US FDA ngoFebhuwari 25, 2014. I-Monovisc idayiswa yiDePuy Synthes, iMitek Sports Medicine ngaphansi kwesivumelwano selayisensi no-Anika.

I-hyaluronan (ushukela oluyinkimbinkimbi yomndeni we-glycosaminoglycan) e-Monovisc yisisindo esikhulu samangqamuzana, i-ultra purified derivative ye-hyaluronan yemvelo evela emthonjeni ongewona wesilwane. I-hyaluronan itholakala kumangqamuzana e-bacterial futhi ixhunyaniswe nesisombululo sokuthengisa. I-Monovisc inikeza umthamo ofanayo no- Orthovisc , omunye u-Anika Therapeutics viscosupplement - kodwa i-Orthovisc inikezwa uchungechunge lwemijovo emithathu esikhundleni sejoza elilodwa.

Izinkomba

I-Monovisc iboniswa ukwelashwa kwe- knee osteoarthritis ezigulini eziye zahluleka ukulashwa, ezifana nezidakamizwa ezingekho izidakamizwa kanye nemithi yezinhlungu ezingekho-narcotic (isib. I- acetaminophen ). Isici esiyinhloko samadolo e-osteoarthritis singumonakalo we- cartilage obangela ubuhlungu obukhulu nokuhamba okulinganiselwe kokunyakaza okuhlangene okuhlangene. Esikhathini se-osteoarthritis, kukhona okungajwayelekile nge- synovial fluid kanye. I-synovial fluid ibamba ukuhlanganiswa ngokujwayelekile, okuvumela ukunyakaza okungahambisani nentambo.

Ama-Viscosupplements, afana ne-Monovisc kanye nabanye abavunyelwe ngaphambilini, babuyela ama-viscous, lubricant properties kuya okuhlangene.

Imiphumela Yokufundwa

Idatha yokuphepha nokusebenza kusukela ekuhlolisweni komtholampilo okungahleliwe, okulawulwa, kabili okubandakanya abahlanganyeli abangu-369 abane-knee osteoarthritis ezindaweni ezingama-31 e-US naseCanada kwakuyisisekelo sokugunyazwa kwe-FDA ye-Monovisc, ngokusho kuka-Anika Therapeutics.

Abahlanganyeli babekwa ngezikhathi ezithile i-Monovisc noma ama-saline injection (ukulawula). Bahlolwe ukuthuthukiswa kobuhlungu obuhlangene besebenzisa i-WOMAC (iWestern Ontario ne-McMaster Universities Osteoarthritis Index), ikakhulukazi befuna iziguli ze-Monovisc eziye zazuza ukuthuthukiswa okukhulu emkhatsini wabo we-WOMAC uma kuqhathaniswa nokulawula iziguli esikhathini esingamaviki angu-12. Ingxenye yokuphepha yokuhlaziywa kwembula "izinga elincane kakhulu lezehlakalo ezimbi" futhi akukho izenzakalo ezimbi kakhulu eziphathelene ne-Monovisc.

Amanye ama-Viscosupplements

I-viscosupplement yokuqala yavunyelwa ngo-1997. Manje kunezinye izi-viscosupplements ezingu-5, eziningi zazo ezidinga uchungechunge lwemijovo esikhundleni sokujola eyodwa.

Ukusebenza kweViscosupplementation

Ngo-2012, umbiko oshicilelwe ku- Annals of Internal Medicine waphetha ngokuthi i-viscosupplementation yayingasebenzi futhi ingozi. Lo mbiko wukuthi i-viscosupplementation ikhiqiza ukunciphisa okungalungile ubuhlungu kuyilapho kungase kwandise ingozi ye-flare-ups nezenzakalo ezimbi. Lesi siphetho sisekelwe ekuhlaziyweni kwemeta kwezilingo ezingu-89 ezingahleliwe ezibandakanya iziguli ezingaphezu kuka-12 000 ze-knee osteoarthritis.

Kodwa i-American Academy of Orthopedic Surgeons ithi, "I-Viscosupplementation ingaba usizo kubantu abane-arthritis abangazange bayiphendule ezithombeni eziyisisekelo. Iphumelela kakhulu uma i-arthritis isesimweni sayo sokuqala (imnene kuya ekulinganiseni.) Ezinye iziguli zingase zizwe ubuhlungu endaweni yokujova, futhi ngezikhathi ezithile izijovo ziholela ekwenzeni ukuvuvukala. Kungathatha amasonto ambalwa ukuqaphela ngcono ngemuva kokuhlolwa kwe-viscosupplementation Akuzona zonke iziguli ezizokwazi ukukhululeka ubuhlungu Uma izijovo ziphumelela zingabuyekezwa emva kwesikhathi, ngokuvamile izinyanga ezingu 6. Ukusebenza kwesikhathi eside kwe-viscosupplementation akukaziwa futhi ucwaningo luqhubeka kule ndawo. "

> Imithombo:

> I-FDA ivumela i-Monovisc, Ukwelashwa Okusha Okukodwa Ukwelashwa Kwezinhlungu Ngenxa ye-Osteoarthritis ye-Knee. Anika Therapeutics. Februwari 25, 2014.
I-Viscosupplementation ye-Osteoarthritis ye-Knee: Ukubuyekeza Okuhlelekile nokuhlaziywa kwe-Meta. Ngo-Agasti 7, 2012. Rutjes et al. Ama-Annal of Medicine yangaphakathi.

> I-Viscosupplementation Ukwelashwa Kwe-Arthritis. I-OrthoInfo. I-AAOS. April 2013.